Eli Lilly (LLY) Other Non Operating Income (2009 - 2012)
Eli Lilly (LLY) posted Other Non Operating Income of -$26.8 million for Q1 2012, down 2336.36% quarter-over-quarter from -$1.1 million in Q4 2011, and down 240.31% year-on-year from $19.1 million in Q2 2011.
Eli Lilly (LLY) Other Non Operating Income (2009 - 2012) Analysis & Trends
Eli Lilly (LLY) has reported Other Non Operating Income for 4 consecutive years, with -$26.8 million the latest figure, recorded in Q1 2012.
- Other Non Operating Income for Q1 2012 came in at -$26.8 million, down 240.31% year-over-year; the trailing twelve-month figure through Mar 2012 was -$118.8 million (down 428.18% YoY), and the FY2011 annual result was -$72.9 million, down 156.69% from the prior year.
- Other Non Operating Income was -$26.8 million for Q1 2012 at Eli Lilly, down from -$1.1 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $111.5 million in Q1 2010 and troughed at -$205.1 million in Q4 2009.
- Average Other Non Operating Income over 4 years is -$12.2 million, with a median of -$1.1 million recorded in 2011.
- Year-over-year, Other Non Operating Income surged 257.71% in 2010 and sank 758.7% in 2011.
- Over 4 years, Other Non Operating Income stood at -$205.1 million in 2009, then jumped by 95.03% to -$10.2 million in 2010, then surged by 89.22% to -$1.1 million in 2011, then tumbled by 2336.36% to -$26.8 million in 2012.
- Per Business Quant data, the three most recent Other Non Operating Income figures were -$26.8 million in Q1 2012, -$1.1 million in Q4 2011, and -$60.6 million in Q3 2011.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2012 | -26.80 Mn |
| Dec 31, 2011 | -1.10 Mn |
| Sep 30, 2011 | -60.60 Mn |
| Jun 30, 2011 | -30.30 Mn |
| Mar 31, 2011 | 19.10 Mn |
| Dec 31, 2010 | -10.20 Mn |
| Sep 30, 2010 | 9.20 Mn |
| Jun 30, 2010 | 18.10 Mn |
| Mar 31, 2010 | 111.50 Mn |
| Dec 31, 2009 | -205.10 Mn |
| Sep 30, 2009 | 66.90 Mn |
| Jun 30, 2009 | 21.40 Mn |
| Mar 31, 2009 | -70.70 Mn |